The Prevalence of Hypovitaminosis D in Patient with Fragility Hip Fracture at a Single Institution in Thailand.

Background: The proportion of people aged 65 years or older continues to increase in Thailand. Consistent with that trend, the number of fragility fracture patients is increasing. Hypovitaminosis D is one of the important factors associated with fragility fracture. Objective: To evaluate serum 25-hydroxyvitamin D (25(OH)D) level and prevalence of hypovitaminosis D in patients with fragility hip fracture in Thailand. Material and Method: This study retrospectively reviewed 25(OH)D level in fragility hip fracture patients treated at Siriraj Hospital between January 2012 and December 2015. Results: Three hundred seventy nine fragility hip fractures were included in this study. Two hundred sixty eight of those patients had serum 25(OH)D level available within one month after fracture. Mean age of patients was 80.8±8.3 years and 74.6% were women. One hundred twenty four patients (46.3%) had vitamin D deficiency (<20 ng/mL) and 86 patients (32.1%) had vitamin D insufficiency (20 to 30 ng/mL). Parathyroid hormone level was available in 159 of 268 patients, and 31.5% of those had hyperparathyroidism (PTH level >65 pg/mL). Conclusion: Orthopedists who treat fragility hip fracture should always include treatment of vitamin D deficiency in their patient management plan. Future studies should establish treatment guidelines regarding dose and duration of vitamin D supplementation in fragility hip fracture patients.

Three-year outcomes of a fracture liaison service model at a university-based tertiary care hospital in Thailand.

Fragility hip fracture (FHF) is a serious complication of osteoporosis. A fracture liaison service (FLS) is crucial in preventing FHF. Our retrospective data of 489 patients with FHF and 3-year follow-ups demonstrated that the FLS improved functional outcomes. Our study's mortality rates were lower than in other published series. PURPOSE: This study assessed the 3-year outcomes after fragility hip fracture (FHF) treatment by a multidisciplinary team from the Siriraj Fracture Liaison Service (Si-FLS). The review investigated the administration rates of anti-osteoporosis medication, refracture, and mortality; activities of daily living; mobility; and health-related quality of life. METHODS: A retrospective review was performed of the records of Si-FLS patients given FHF treatment between June 2016 and October 2018. The outcomes were evaluated at 3 time points: before discharge, and 1 and 3 years after treatment. RESULTS: The study enrolled 489 patients (average age, 78). The mortality and refracture rates at 1 year after hip fracture were 13.9% and 1.6%, respectively. At the 3-year follow-up, both rates were higher (20.4% and 5.7%, respectively). The Barthel Index and EuroQoL Visual Analogue Scale had risen to a plateau at the 1-year follow-up and remained stable to the 3-year follow-up. One year after treatment, approximately 60% of the patients could ambulate outdoors, and the proportion remained steady until the 3-year follow-up. There was no difference in the 1- and 3-year follow-up anti-osteoporosis medication administration rates (approximately 40%). CONCLUSIONS: This study confirms the benefits of having a multidisciplinary FLS care team to manage older people with FHF. An FLS improves the care of patients with FHF and the social support of caregivers and relatives. The FLS maintained the functional outcomes of the patients through 3 years of postfracture treatment.